Pancreatic Cancer Research

ResearcherPeking University First HospitalActive in the last 2 years

Xiaodong Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3129-2662; OpenAlex author ID A5087875618. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 4 papers

Papers 21

  1. Tumor-derived exosomes: Unravelling the pathogenesis of pancreatic cancer with liver metastases and exploring the potential for clinical translation. Co-author DOI 10.1016/j.canlet.2024.217403↗
  2. Multi-omics analysis of polyamine metabolism implicates NT5E/CD73 in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217887↗
  3. SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113713↗
  4. Current status and future prospects of cancer-derived immunoglobulins in pancreatic cancer. Last author DOI 10.7150/jca.109497↗
  5. Machine learning algorithm integrates bulk and single-cell transcriptome sequencing to reveal immune-related personalized therapy prediction features for pancr… Co-author DOI 10.18632/aging.205293↗
  6. Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1. Co-author DOI 10.1097/cm9.0000000000002154↗
  7. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Co-author DOI 10.1016/j.canlet.2020.06.009↗
  8. High mobility group AT-hook 2 promotes tumorigenicity of pancreatic cancer cells via upregulating ANLN. Co-author DOI 10.1016/j.yexcr.2020.112088↗
  9. LncRNA H19-Derived miR-675-3p Promotes Epithelial-Mesenchymal Transition and Stemness in Human Pancreatic Cancer Cells by targeting the STAT3 Pathway. Co-author DOI 10.7150/jca.44833↗
  10. BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2019.02.031↗
  11. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagi… First author DOI 10.1002/ijc.31211↗
  12. Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer … Co-author DOI 10.1021/acsnano.8b01573↗
  13. Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. Co-author DOI 10.3892/or.2018.6178↗
  14. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Co-author DOI 10.1016/j.canlet.2017.05.006↗
  15. Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem-Like Cells. Co-author DOI 10.7150/jca.13305↗
  16. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Co-author DOI 10.1007/s10620-013-2673-2↗
  17. Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis. First author DOI 10.3892/or.2012.2210↗
  18. Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells. Co-author DOI 10.1007/s10620-012-2036-4↗
  19. Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. Co-author DOI 10.3892/or.2012.1808↗
  20. [Effects and mechanisms of combined suppression of epidermal growth factor receptor and hedgehog signaling on proliferation in pancreatic cancer cells]. First author PMID 22944238↗
  21. [Regulatory mechanisms of Hedgehog signaling pathway for epithelial-mesenchymal transition in pancreatic cancer cells]. Co-author PMID 22340649↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yinmo Yang · 12 shared papers, 2013–2025 · strength 1.61
  2. Yongsu Ma · 5 shared papers, 2018–2025 · strength 0.94
  3. Zhengkui Zhang · 8 shared papers, 2016–2022 · strength 0.71
  4. Ling Ma · 6 shared papers, 2016–2022 · strength 0.56
  5. Yinmo Yang · 7 shared papers, 2011–2025 · strength 0.53
  6. Huahu Guo · 5 shared papers, 2017–2020 · strength 0.49
  7. Mingzhe Li · 3 shared papers, 2020–2025 · strength 0.49
  8. Feng Wang · 5 shared papers, 2016–2022 · strength 0.45
  9. Marko Kornmann · 5 shared papers, 2016–2020 · strength 0.42
  10. Chong Du · 4 shared papers, 2017–2019 · strength 0.30
  11. Xiangyu Chu · 1 shared paper, 2025 · strength 0.28
  12. Dongqi Li · 1 shared paper, 2025 · strength 0.28
  13. Xin Wang · 1 shared paper, 2025 · strength 0.26
  14. Shan-Wen Chen · 1 shared paper, 2025 · strength 0.26
  15. Yiran Chen · 1 shared paper, 2025 · strength 0.26
  16. Rui Ma · 1 shared paper, 2025 · strength 0.26
  17. Xiaoxue Pan · 1 shared paper, 2025 · strength 0.26
  18. Chang-fu Qin · 6 shared papers, 2011–2013 · strength 0.24
  19. Kun Hao · 6 shared papers, 2011–2013 · strength 0.24
  20. Baoyi Li · 1 shared paper, 2025 · strength 0.20
  21. Enkui Zhang · 1 shared paper, 2025 · strength 0.20
  22. Yingjin Wang · 1 shared paper, 2025 · strength 0.20
  23. Yazhou Wang · 2 shared papers, 2018–2020 · strength 0.20
  24. Longjun Zang · 1 shared paper, 2023 · strength 0.19
  25. Qingwang Miao · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.